Betamethasone microspheres
Alternative Names: Betamethasone DDS; DE-102Latest Information Update: 05 Nov 2023
At a glance
- Originator Santen Pharmaceutical
- Class Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules; Steroids
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetic macular oedema; Retinal oedema
Most Recent Events
- 15 Jun 2015 No recent reports of development identified - Phase-II/III for Diabetic macular oedema in Japan (Injection)
- 15 Jun 2015 No recent reports of development identified - Phase-II/III for Retinal oedema in Japan, South Korea (Injection)
- 18 Jul 2014 Santen Pharmaceuticals completes a phase II/III trial in Diabetic macular oedema in Japan (NCT01411254)